Development of a Novel Synthetic Drug for Osteoporosis and Fracture Healing
Abstract
This is a progress report (year 1) for developing a novel therapeutic drug for skeletal diseases, in particular focusing on administration of salubrinal for treatment of osteoporosis and bone fracture. A formulation for salubrinal was determined and an effective dosage was identified. Using ovariectomized mice, administration of salubrinal was shown to reduce body weight and fat weight, and to prevent reduction in uterus weight and BMD/BMC. Salubrinal was also shown to inhibit osteoclast development and to stimulate osteoblast development through regulation of key transcription factors such as ATF4, NF B, and NFATc1. A pathway analysis revealed that the observed effects of salubrinal were mediated by eIF2 , p38 MAPK, and NF B pathways. Multiple invention disclosures and patents were submitted or being prepared for bone remodeling, fat metabolism, joint preservation, cancer treatment, and salubrinal coating on transplantable materials. A collaborative relationship was established with Zimmer Co. Two research abstracts were submitted, two peer-reviewed articles are in press, and one peer-reviewed research article was submitted.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2012
- Accession Number
- ADA570122
Entities
People
- Hiroki Yokota
Organizations
- Indiana University